CareDx, Inc (NASDAQ:CDNA – Get Free Report) saw a significant decline in short interest during the month of August. As of August 15th, there was short interest totalling 3,210,000 shares, a decline of 7.8% from the July 31st total of 3,480,000 shares. Based on an average daily trading volume, of 913,600 shares, the days-to-cover ratio is currently 3.5 days. Currently, 6.5% of the shares of the company are short sold.
Analysts Set New Price Targets
Several analysts have recently commented on the stock. The Goldman Sachs Group raised their target price on shares of CareDx from $16.00 to $26.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Raymond James lowered CareDx from an “outperform” rating to a “market perform” rating in a report on Monday, May 13th. HC Wainwright reissued a “neutral” rating on shares of CareDx in a report on Thursday, August 1st. Wells Fargo & Company started coverage on shares of CareDx in a research note on Tuesday, August 27th. They set an “underweight” rating and a $28.00 price target on the stock. Finally, BTIG Research upgraded shares of CareDx from a “neutral” rating to a “buy” rating and set a $40.00 price objective for the company in a research note on Monday, August 19th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $28.80.
View Our Latest Analysis on CareDx
Insider Buying and Selling at CareDx
Hedge Funds Weigh In On CareDx
A number of institutional investors have recently made changes to their positions in CDNA. Millennium Management LLC increased its position in CareDx by 1,085.4% during the 2nd quarter. Millennium Management LLC now owns 2,140,909 shares of the company’s stock worth $33,248,000 after purchasing an additional 1,960,308 shares in the last quarter. Bamco Inc. NY purchased a new stake in shares of CareDx during the first quarter worth about $13,025,000. Fred Alger Management LLC raised its position in shares of CareDx by 517.9% in the second quarter. Fred Alger Management LLC now owns 1,149,602 shares of the company’s stock valued at $17,853,000 after buying an additional 963,554 shares during the last quarter. Driehaus Capital Management LLC purchased a new position in shares of CareDx during the second quarter valued at approximately $2,852,000. Finally, Vanguard Group Inc. lifted its stake in shares of CareDx by 4.4% during the first quarter. Vanguard Group Inc. now owns 4,300,016 shares of the company’s stock valued at $45,537,000 after buying an additional 180,334 shares during the period.
CareDx Stock Performance
NASDAQ CDNA traded down $1.32 during trading hours on Tuesday, reaching $29.41. The company’s stock had a trading volume of 690,670 shares, compared to its average volume of 914,764. The stock has a market cap of $1.53 billion, a PE ratio of -8.76 and a beta of 1.78. The company’s 50-day moving average is $22.35 and its two-hundred day moving average is $15.23. CareDx has a fifty-two week low of $4.80 and a fifty-two week high of $34.84.
CareDx (NASDAQ:CDNA – Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.37. CareDx had a negative net margin of 53.73% and a negative return on equity of 53.65%. The business had revenue of $92.27 million during the quarter, compared to analysts’ expectations of $67.20 million. Equities analysts expect that CareDx will post -0.84 earnings per share for the current fiscal year.
About CareDx
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Read More
- Five stocks we like better than CareDx
- What is a Stock Market Index and How Do You Use Them?
- 3 Small Cap Stocks That Insiders Are Buying
- Stock Market Sectors: What Are They and How Many Are There?
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- What to Know About Investing in Penny Stocks
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.